Purpose: Intravitreal injections can cause several ocular complications, including vitreous hemorrhage, endophthalmitis, retinal detachment, and cataract, and clearly repeated injections can multiply the risk of these complications. Bevacizumab is used for the treatment of different ocular diseases. For improvement of drug availability after intravitreal administration, in this study, liposomal bevacizumab as a novel drug delivery system was prepared and compared with conventional formulas in the market.
B evacizumab (Avastin) is a synthetic monoclonal antibody against vascular endothelial growth factor with the molecular weight of 149 kd, which is approved by the Food and Drug Administration for colorectal cancer treatment. In addition, intravitreal injection of bevacizumab is recently used for treatment of several ocular diseases. Different studies demonstrate increasing indications of this drug and its beneficial effects on age-related macular degeneration, 1,2 myopic choroidal neovascularization, 3 neovascular glaucoma, 4 persistent diabetic macular edema, 5 proliferative diabetic retinopathy, 6 and retinal vein occlusions. 7 These studies have shown that bevacizumab effectively reduces neovascular activity and vascular permeability in different ocular tissues.
Bevacizumab is a very effective drug in several ocular diseases, but unfortunately its effect is short lived (its intravitreal half-life in different animal and human studies was measured at 3-5 days) and several intravitreal injections are needed for maintaining a therapeutic effect. 1, 2 The main concerns are difficulty of repeated injections and complication of these injections including intravitreal hemorrhage, endophthalmitis, retinal detachment, cataract, and opening of the sclerotomy site. 8, 9 Therefore, primary fast release and the following controlled release of the drug in all these conditions is ideal. Despite limited human studies, pharmacokinetic and pharmacologic studies of drug-containing liposomes in animal studies have shown several benefits of the liposomal form such as lowering the toxicity and prolonging the therapeutic effect. 10 Liposomes are 2-layer microscopic vesicles surrounding water spaces that measure 20 nm to several micrometers. Many features of liposomes such as low toxicity, biodegradation, and lack of immunogenicity make them a good drug delivery system. 11, 12 Using liposomes for intravitreal injection can lead to the slow and controlled release of drugs in vitreous and probably a decrease in the number of injections.
Application of liposomes for intravitreal administration has been evaluated by numerous studies. The effect of liposome encapsulation on the pharmacokinetics of gentamicin after intravitreal injection in albino rabbits was investigated by Fishman et al. 13 The results showed that administration of these liposomes improved the concentration time profile in the normal rabbit eye. Peyman et al 14 determined the intravitreal clearance of liposome encapsulated ganciclovir. They reported that total ganciclovir concentrations in the vitreous (up to 28 days) were higher than ID 50 for different clinical and laboratory strains of herpes simplex viruses. Intravitreal liposome encapsulated clindamycin for possible treatment in experimentally induced bacterial endophthalmitis on rabbits was investigated by Rao et al 15 and Fiscella et al 16 assayed intravitreal liposome encapsulated clindamycin. They found the concentration to be 28 g/mL after 48 hours, whereas the nonencapsulated drug concentration was Ͻ2.30 g/mL after 24 hours. Clearance of liposome-bound cyclosporine after intravitreal injection was reported by Alghadyan et al. 17 It was reported that the half-life of free cyclosporine was ϳ6 hours and that of liposome-bound cyclosporine was ϳ3 days. Vasoactive intestinal peptide was formulated in a liposomal formulation by Lajavardi et al. 18 Concentration of vasoactive intestinal peptide after intravitreal injection was 15 times higher in ocular fluid than the concentration achieved by administration of vasoactive intestinal peptide solution alone. Application of antisense oligonucleotides (ODNs) encapsulated in liposomes have been studied for their potential to treat ocular disorders by Bochot et al. 19 The results showed that liposomal formulation can release ODNs in a sustained manner after intravitreal injection.
In this study, liposomes encapsulated bevacizumab were prepared and characterized. The vitreous and aqueous concentration-time profile was determined in an animal model after intravitreal injection of bevacizumab solution and liposomal bevacizumab showed the potential benefits of this novel drug delivery system for treatment of ocular diseases.
Materials and Methods

Materials
Bevacizumab (Avastin) was from Genentech/Roche (San Francisco, CA). The lipids used were egg phosphatidylcholine (Avanti Polar Lipids Inc., Alabaster, AL) and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids Inc.). Cholesterol was obtained from Sigma (St. Louis, MO). Ketamine hydrochloride and xylazine were from Alfasan (Holland). Monoclonal antihuman IgG1 (Fab specific) antibody produced in mice and antihuman IgG (Fc specific)-peroxidase antibody produced in goats were purchased from Sigma. All other materials and solvents were of analytical grade.
Preparation of Liposomes-containing Bevacizumab
For the preparation of liposomes-containing bevacizumab, dehydration-rehydration method was used. 20 Briefly, phospholipid (egg phosphatidylcholine or 1,2-dipalmitoyl-sn-glycero-3-phosphocholine) and cholesterol with molar ratio of 1:1 were dissolved in a minimum amount of methanol:chloroform (2:1). This solution in a round bottom flask was connected to the rotary evaporator (Buchi, Switzerland) to evaporate solvent under reduced pressure and to deposit lipid film. For the complete elimination of trace amounts of solvent, the flask was connected to a freeze dryer (Christ, Germany) overnight. Then, lipid film was hydrated by a phosphate-buffered saline (0.1 mmol/L, pH 7.4) for 30 minutes. Then, the prepared liposomes were extruded 11 times by a Thermobarrel extruder (Northern Lipids, Canada) through a 100-nm polycarbonate filter (Nuclepore Track-Etch Membrane, Whatman). To 1 mL of this liposome (phospholipid concentration ϭ 32 mol/mL), 1 mL bevacizumab (Avastin) was added. After freezing of this mixture, the frozen liposome was vacuum dried in the freeze drier (Taitec, Japan) for 12 hours. The dried material was rehydrated by distillated water to form liposome suspension.
Determination of Encapsulation Efficiency
For determination of encapsulation efficiency, an indirect method was used. Briefly, after centrifugation of liposomes at 14,000 rpm for 20 minutes, the supernatant was filtrated through a 0.45-m nylon filter, and the concentration of bevacizumab in the samples was determined by enzyme-linked immunosorbent assay (ELISA). The encapsulation efficiency was determined by subtracting the amount of free drug in the supernatant from the total. Results were reported by mean Ϯ SD for n ϭ 3.
Enzyme-linked Immunosorbent Assay Studies
For quantitating of bevacizumab concentrations, sandwich ELISA was used. ELISA plates were coated with 5 g/mL of monoclonal antihuman IgG1 (Fab specific) antibody in 50-mM carbonate buffer, pH 9.6 at 4°C overnight and blocked with phosphate-buffered saline-1% bovine serum albumin at room temperature for 1 hour. Serial dilutions of samples in phosphatebuffered saline were incubated on the plates for 2 hours. Bound bevacizumab was detected using antihuman IgG (Fc specific)-peroxidase antibody as the substrate. Plates were washed between steps. Absorbance was read at 450 nm on the plate reader (Statfax-2100, Awareness Technology, Palm City, FL).
Animal Studies
New Zealand albino-rabbits, weighing 1.8 kg to 2.0 kg, were used in the study. Rabbits were sedated with 60 mg/kg of intramuscular ketamine hydrochloride, 6 mg/mL of intramuscular xylazine hydrochloride, and eyes were anesthetized with topical administration of 1% tetracaine ophthalmic drop. Before the injection, povidone iodine 5% was applied on the surface of the eye for 2 minutes. After washing with BSS, the eyes of each rabbit received an intravitreal injection of 1.25 mg bevacizumab 2.5 mm behind the limbus in the superotemporal quadrant using a 30-gauge needle. The left eyes were injected by liposomal bevacizumab, and right eyes received nonliposomal bevacizumab (bevacizumab solution). Eyes were monitored repeatedly for signs of inflammation. Rabbits were killed at Days 3, 7, 14, 28, and 42 after the intravitreal injection, three animals each day, by intravenous pentobarbital overdose.
Both eyes were immediately enucleated, aqueous humor was aspirated with a 30-gauge needle via an anterior limbal parasynthesis. Then the corneas were cut off, crystalline lenses were removed in an open sky extracapsular cataract extraction fashion, the posterior capsule of the lens and anterior hyaloids face was severed and the whole of the vitreous was aspirated. The aqueous humor and vitreous were then immediately frozen at Ϫ80°C. Before analysis, the frozen aqueous humor and vitreous were defrosted overnight at 4°C. The next day, the samples were centrifuged at 14,000 rpm for 10 minutes. All samples were diluted as necessary. Bevacizumab concentrations were measured in whole vitreous and aqueous fluid by ELISA. As a control, some eyes received empty liposomes and some eyes were not injected. The animal protocol was approved by the local ethical committee.
Results
The liposomes prepared by the dehydration-rehydration method were morphologically multilamellar vesicles, as observed under an optical microscope. To achieve sterile liposome for this animal study, they were filtrated through 0.22-m filters. The encapsulation efficiencies of different liposomal formulations were summarized in Table 1 . According to these results, egg phosphatidylcholine: CHOL formulation was chosen for animal study. Figure 1 shows the change in bevacizumab concentration over time in the vitreous of the injected eyes. A vitreous concentration of bevacizumab was 246 and 163 g/mL in left (received liposomal bevacizumab) and right eyes (received nonliposomal bevacizumab) after 3 days, respectively. Vitreous concentration of bevacizumab declined during time. Concentrations of 48 and 28 g/mL of bevacizumab were maintained in the vitreous humor of left and right eyes after 28 days. The final concentration after 42 days of administration Mean Ϯ SD, n ϭ 3. DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; EPC, egg phosphatidylcholine; CHOL, cholesterol.
was 16 and 3.3 g/mL in the eyes that received liposomal and nonliposomal bevacizumab, respectively. Areas under the drug concentration time curve for liposomal bevacizumab was 1.5-fold higher when compared with nonliposomal bevacizumab (5,270 and 3,877 g ϫ d/mL). Also it was shown that the clearance of bevacizumab in vitreous from liposomal formulations was slower than the soluble form (0.23 and 0.32 mL/d).
Variation in bevacizumab concentration in the aqueous humor after intravitreal injection was presented in Figure 2 . Drug concentrations in the aqueous humor of the injected eye reached a peak concentration of 18 and 14 g/mL, 3 days after drug administration. This concentration went down to 10.2 and 6.5 g/mL 14 days after drug injection, and the concentration fell to 1.25, 0.5 g/mL 42 days after intravitreal administration. No adverse event was observed in the animal model and the treatment was well tolerated.
Discussion
Because of blood-ocular barriers, intravitreal concentration of many parenteral agents are not adequate and also large molecules such as proteins do not cross this tight barrier. 21 For these reasons, intravitreal injection is necessary in some cases of vitreoretinal diseases. On the other hand, multiple injections have often been required to achieve desired treatment and increasing the dose in an effort to prolong the efficacy of individual injections might expose the patient to toxicity from high concentrations. 22 Novel drug delivery systems such as liposomes, 23-25 microspheres, 21, 26, 27 and iontophoresis 28 can obviate the need for repeated injections. The use of liposomal vehicles to prolong clearance and limit peak concentrations after intravitreal injection might avert the risks of frequent intravitreal injections. 22 In this study, liposomes encapsulated bevacizumab were prepared and characterized. Then the efficacy of these liposomes was evaluated in vivo. The results of this study showed that the duration of therapeutic levels can be increased with liposomal encapsulation of the drug.
The dehydration-rehydration method used for preparation of liposomes has yielded high drug encapsulation percentages of soluble drugs. 20 The encapsulation ratio of the drug depends on different parameters including characteristics of the drug, molar ratios, characteristics of the lipids used, and the method of preparation. It was reported that the addition of cholesterol to formulation can retard the clearance and increase the half-life, 10 so that we added the cholesterol to the liposomal formulation. Also it was indicated that small unilamellar vesicles have a shorter half-life than large unilamellar vesicles, 29 so that large unilamellar vesicles liposomes were used for animal studies. Filtration of multilamellar vesicles through 0.22-m filters reduces the liposome size and converts multilamellar vesicles to large unilamellar vesicles. Gel electrophoresis experiments were used to investigate the stability of bevacizumab after encapsulation in liposomes. The results of this study confirmed that bevacizumab is stable during the preparation process (data not shown).
In the previous studies, the rabbit model was used to study intravitreal pharmacokinetics of drugs. Therefore, in this study, rabbits were used in the animal study. The pharmacokinetics of bevacizumab after intravitreal injection was evaluated in 2007. 30 It was reported that the half-life of intravitreal injection of 1.25-mg bevacizumab is 4.32 days and the concentration of bevacizumab in vitreous was higher than 10 g/mL 30 days after drug administration. Our data support these results.
As it was shown in previous studies, retinal neovascularization in diabetics responds to very low doses of bevacizumab (6.2 g). 6, 30 In this study, concentration of bevacizumab in vitreous after administration of liposomal formulation was three times higher than this therapeutic amount, so in this case one injection can achieve the vitreous concentration above the therapeutic level for at least 42 days.
In conclusion, intravitreal injection of liposomes encapsulated bevacizumab was well tolerated through 42 days in rabbits. The clearance of this drug in vitreous from liposomal formulations was slower than the soluble form. The concentration level of bevacizumab after intravitreal injection suggests that intravitreal injection of drug by these carriers provide sufficient concentration of therapeutic drug for Ͼ6 weeks for diabetic neovascularization and maybe other neovascular eye diseases.
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